+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dopamine Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 89 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 6090510
Description Jump to:
Dopamine agonists, used for Parkinson’s disease, restless legs syndrome (RLS), hyperprolactinemia, and other conditions, mimic dopamine to manage neurological and hormonal disorders. The market is driven by the rising prevalence of Parkinson’s disease, affecting 55 million people globally and projected to reach 70 million by 2030, and RLS, with a 5-10% prevalence. The aging population, with 1 billion over 60 in 2020 and projected to reach 2.1 billion by 2050, increases demand. Advanced formulations like transdermal patches and extended-release tablets improve compliance by 30%. The global dopamine agonist market is estimated at USD 700-1,300 million in 2025, with a CAGR of 3%-7% through 2030.

Regional Market Trends

  • North America: The U.S. leads with advanced Parkinson’s care, while Canada focuses on RLS management.
  • Europe: Germany, France, and the UK drive growth with robust neurology services.
  • Asia Pacific: China and India see rising demand due to aging populations, with Japan emphasizing novel formulations.
  • Rest of the World: Brazil expands access to generics, while the Middle East addresses neurological care.

Application Analysis

  • Parkinson’s Disease: Expected growth of 3.5%-7.5%, driven by high prevalence. Trends focus on transdermal patches.
  • Restless Legs Syndrome (RLS): Projected growth of 3.2%-7.2%, linked to symptom relief. Advances emphasize low-dose therapies.
  • Hyperprolactinemia: Anticipated growth of 2.8%-6.8%, suited for hormonal disorders. Trends highlight oral formulations.
  • Others: Expected growth of 2.5%-6.5%, covering niche indications. Developments prioritize combination therapies.

Type Analysis

  • Ergot Alkaloids: Expected growth of 2.5%-6.5%, used in specific cases. Trends focus on limited use due to side effects.
  • Non-Ergot Dopamine Agonists: Projected growth of 3.8%-7.8%, favored for safety. Advances emphasize extended-release forms.

Key Market Players

  • GSK: Offers ropinirole for Parkinson’s and RLS.
  • Boehringer Ingelheim: Develops pramipexole formulations.
  • Pfizer: Provides dopamine agonists for neurological disorders.
  • Teva Pharmaceutical: Supplies affordable generics.
  • Novartis: Focuses on innovative delivery systems.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Low, due to high R&D costs and regulatory barriers.
  • Threat of Substitutes: Moderate, with levodopa competing in Parkinson’s, but agonists are preferred for early-stage treatment.
  • Bargaining Power of Buyers: High, as generics increase price competition.
  • Bargaining Power of Suppliers: Low, with multiple API providers.
  • Competitive Rivalry: Moderate, with players competing on formulation and cost.

Market Opportunities and Challenges

Opportunities:

  • Addressing Parkinson’s disease, affecting 55 million people.
  • Managing RLS, with 5-10% prevalence.
  • Leveraging an aging population, projected to reach 2.1 billion by 2050.
  • Utilizing advanced formulations, improving compliance by 30%.
  • Supporting early diagnosis in neurological disorders.
  • Expanding access to generics in emerging markets.

Challenges:

  • Side effects like impulse control disorders requiring monitoring.
  • Competition from alternative therapies like levodopa.
  • Regulatory delays for novel formulations.
  • Price erosion due to generics.
  • Limited awareness in low-income regions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Dopamine Agonist Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Dopamine Agonist Market in North America (2020-2030)
8.1 Dopamine Agonist Market Size
8.2 Dopamine Agonist Market by End Use
8.3 Competition by Players/Suppliers
8.4 Dopamine Agonist Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Dopamine Agonist Market in South America (2020-2030)
9.1 Dopamine Agonist Market Size
9.2 Dopamine Agonist Market by End Use
9.3 Competition by Players/Suppliers
9.4 Dopamine Agonist Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Dopamine Agonist Market in Asia & Pacific (2020-2030)
10.1 Dopamine Agonist Market Size
10.2 Dopamine Agonist Market by End Use
10.3 Competition by Players/Suppliers
10.4 Dopamine Agonist Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Dopamine Agonist Market in Europe (2020-2030)
11.1 Dopamine Agonist Market Size
11.2 Dopamine Agonist Market by End Use
11.3 Competition by Players/Suppliers
11.4 Dopamine Agonist Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Dopamine Agonist Market in MEA (2020-2030)
12.1 Dopamine Agonist Market Size
12.2 Dopamine Agonist Market by End Use
12.3 Competition by Players/Suppliers
12.4 Dopamine Agonist Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Dopamine Agonist Market (2020-2025)
13.1 Dopamine Agonist Market Size
13.2 Dopamine Agonist Market by End Use
13.3 Competition by Players/Suppliers
13.4 Dopamine Agonist Market Size by Type
Chapter 14 Global Dopamine Agonist Market Forecast (2025-2030)
14.1 Dopamine Agonist Market Size Forecast
14.2 Dopamine Agonist Application Forecast
14.3 Competition by Players/Suppliers
14.4 Dopamine Agonist Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 GSK
15.1.1 Company Profile
15.1.2 Main Business and Dopamine Agonist Information
15.1.3 SWOT Analysis of GSK
15.1.4 GSK Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.2 Boehringer Ingelheim
15.2.1 Company Profile
15.2.2 Main Business and Dopamine Agonist Information
15.2.3 SWOT Analysis of Boehringer Ingelheim
15.2.4 Boehringer Ingelheim Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.3 Pfizer
15.3.1 Company Profile
15.3.2 Main Business and Dopamine Agonist Information
15.3.3 SWOT Analysis of Pfizer
15.3.4 Pfizer Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.4 Teva Pharmaceutical
15.4.1 Company Profile
15.4.2 Main Business and Dopamine Agonist Information
15.4.3 SWOT Analysis of Teva Pharmaceutical
15.4.4 Teva Pharmaceutical Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.5 UCB Pharma
15.5.1 Company Profile
15.5.2 Main Business and Dopamine Agonist Information
15.5.3 SWOT Analysis of UCB Pharma
15.5.4 UCB Pharma Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.6 Novartis
15.6.1 Company Profile
15.6.2 Main Business and Dopamine Agonist Information
15.6.3 SWOT Analysis of Novartis
15.6.4 Novartis Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.7 VeroScience
15.7.1 Company Profile
15.7.2 Main Business and Dopamine Agonist Information
15.7.3 SWOT Analysis of VeroScience
15.7.4 VeroScience Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.8 Supernus Pharmaceuticals
15.8.1 Company Profile
15.8.2 Main Business and Dopamine Agonist Information
15.8.3 SWOT Analysis of Supernus Pharmaceuticals
15.8.4 Supernus Pharmaceuticals Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.9 Lundbeck
15.9.1 Company Profile
15.9.2 Main Business and Dopamine Agonist Information
15.9.3 SWOT Analysis of Lundbeck
15.9.4 Lundbeck Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
15.10 Amneal Pharmaceuticals
15.10.1 Company Profile
15.10.2 Main Business and Dopamine Agonist Information
15.10.3 SWOT Analysis of Amneal Pharmaceuticals
15.10.4 Amneal Pharmaceuticals Dopamine Agonist Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Dopamine Agonist Report
Table Data Sources of Dopamine Agonist Report
Table Major Assumptions of Dopamine Agonist Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Dopamine Agonist Picture
Table Dopamine Agonist Classification
Table Dopamine Agonist Applications
Table Drivers of Dopamine Agonist Market
Table Restraints of Dopamine Agonist Market
Table Opportunities of Dopamine Agonist Market
Table Threats of Dopamine Agonist Market
Table COVID-19 Impact For Dopamine Agonist Market
Table Raw Materials Suppliers
Table Different Production Methods of Dopamine Agonist
Table Cost Structure Analysis of Dopamine Agonist
Table Key End Users
Table Latest News of Dopamine Agonist Market
Table Merger and Acquisition
Table Planned/Future Project of Dopamine Agonist Market
Table Policy of Dopamine Agonist Market
Table 2020-2030 North America Dopamine Agonist Market Size
Figure 2020-2030 North America Dopamine Agonist Market Size and CAGR
Table 2020-2030 North America Dopamine Agonist Market Size by Application
Table 2020-2025 North America Dopamine Agonist Key Players Revenue
Table 2020-2025 North America Dopamine Agonist Key Players Market Share
Table 2020-2030 North America Dopamine Agonist Market Size by Type
Table 2020-2030 United States Dopamine Agonist Market Size
Table 2020-2030 Canada Dopamine Agonist Market Size
Table 2020-2030 Mexico Dopamine Agonist Market Size
Table 2020-2030 South America Dopamine Agonist Market Size
Figure 2020-2030 South America Dopamine Agonist Market Size and CAGR
Table 2020-2030 South America Dopamine Agonist Market Size by Application
Table 2020-2025 South America Dopamine Agonist Key Players Revenue
Table 2020-2025 South America Dopamine Agonist Key Players Market Share
Table 2020-2030 South America Dopamine Agonist Market Size by Type
Table 2020-2030 Brazil Dopamine Agonist Market Size
Table 2020-2030 Argentina Dopamine Agonist Market Size
Table 2020-2030 Chile Dopamine Agonist Market Size
Table 2020-2030 Peru Dopamine Agonist Market Size
Table 2020-2030 Asia & Pacific Dopamine Agonist Market Size
Figure 2020-2030 Asia & Pacific Dopamine Agonist Market Size and CAGR
Table 2020-2030 Asia & Pacific Dopamine Agonist Market Size by Application
Table 2020-2025 Asia & Pacific Dopamine Agonist Key Players Revenue
Table 2020-2025 Asia & Pacific Dopamine Agonist Key Players Market Share
Table 2020-2030 Asia & Pacific Dopamine Agonist Market Size by Type
Table 2020-2030 China Dopamine Agonist Market Size
Table 2020-2030 India Dopamine Agonist Market Size
Table 2020-2030 Japan Dopamine Agonist Market Size
Table 2020-2030 South Korea Dopamine Agonist Market Size
Table 2020-2030 Southeast Asia Dopamine Agonist Market Size
Table 2020-2030 Australia Dopamine Agonist Market Size
Table 2020-2030 Europe Dopamine Agonist Market Size
Figure 2020-2030 Europe Dopamine Agonist Market Size and CAGR
Table 2020-2030 Europe Dopamine Agonist Market Size by Application
Table 2020-2025 Europe Dopamine Agonist Key Players Revenue
Table 2020-2025 Europe Dopamine Agonist Key Players Market Share
Table 2020-2030 Europe Dopamine Agonist Market Size by Type
Table 2020-2030 Germany Dopamine Agonist Market Size
Table 2020-2030 France Dopamine Agonist Market Size
Table 2020-2030 United Kingdom Dopamine Agonist Market Size
Table 2020-2030 Italy Dopamine Agonist Market Size
Table 2020-2030 Spain Dopamine Agonist Market Size
Table 2020-2030 Belgium Dopamine Agonist Market Size
Table 2020-2030 Netherlands Dopamine Agonist Market Size
Table 2020-2030 Austria Dopamine Agonist Market Size
Table 2020-2030 Poland Dopamine Agonist Market Size
Table 2020-2030 Russia Dopamine Agonist Market Size
Table 2020-2030 MEA Dopamine Agonist Market Size
Figure 2020-2030 MEA Dopamine Agonist Market Size and CAGR
Table 2020-2030 MEA Dopamine Agonist Market Size by Application
Table 2020-2025 MEA Dopamine Agonist Key Players Revenue
Table 2020-2025 MEA Dopamine Agonist Key Players Market Share
Table 2020-2030 MEA Dopamine Agonist Market Size by Type
Table 2020-2030 Egypt Dopamine Agonist Market Size
Table 2020-2030 Israel Dopamine Agonist Market Size
Table 2020-2030 South Africa Dopamine Agonist Market Size
Table 2020-2030 Gulf Cooperation Council Countries Dopamine Agonist Market Size
Table 2020-2030 Turkey Dopamine Agonist Market Size
Table 2020-2025 Global Dopamine Agonist Market Size by Region
Table 2020-2025 Global Dopamine Agonist Market Size Share by Region
Table 2020-2025 Global Dopamine Agonist Market Size by Application
Table 2020-2025 Global Dopamine Agonist Market Share by Application
Table 2020-2025 Global Dopamine Agonist Key Vendors Revenue
Figure 2020-2025 Global Dopamine Agonist Market Size and Growth Rate
Table 2020-2025 Global Dopamine Agonist Key Vendors Market Share
Table 2020-2025 Global Dopamine Agonist Market Size by Type
Table 2020-2025 Global Dopamine Agonist Market Share by Type
Table 2025-2030 Global Dopamine Agonist Market Size by Region
Table 2025-2030 Global Dopamine Agonist Market Size Share by Region
Table 2025-2030 Global Dopamine Agonist Market Size by Application
Table 2025-2030 Global Dopamine Agonist Market Share by Application
Table 2025-2030 Global Dopamine Agonist Key Vendors Revenue
Figure 2025-2030 Global Dopamine Agonist Market Size and Growth Rate
Table 2025-2030 Global Dopamine Agonist Key Vendors Market Share
Table 2025-2030 Global Dopamine Agonist Market Size by Type
Table 2025-2030 Dopamine Agonist Global Market Share by Type

Companies Mentioned

  • GSK
  • Boehringer Ingelheim
  • Pfizer
  • Teva Pharmaceutical
  • UCB Pharma
  • Novartis
  • VeroScience
  • Supernus Pharmaceuticals
  • Lundbeck
  • Amneal Pharmaceuticals

Related Topics

Related Reports

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 153 Pages
  • Global
From
Dopamine Agonists Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Dopamine Agonists Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From
Dopamine Agonists Market Report 2025 - Product Image

Dopamine Agonists Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Oral Antiparkinsonian Drugs Market - Global Forecast 2025-2030 - Product Image

Oral Antiparkinsonian Drugs Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Neuroregeneration Therapy - Global Strategic Business Report - Product Image

Neuroregeneration Therapy - Global Strategic Business Report

  • Report
  • 480 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.